Keyword: U.S. Federal Trade Commission
A set of Medicare payers accuse embattled Mallinckrodt of violating antitrust law to stifle competition for its $1 billion-plus Acthar Gel.
Sanofi has ratcheted up the legal pressure on Mylan with a lawsuit claiming the EpiPen maker abused its monopoly position to “squelch” competition, including the French pharma's own Auvi-Q.
Persistence has paid off for a group of drug purchasers that sued Mylan over delays to generics of Teva’s narcolepsy med Provigil.
The EpiPen saga isn’t over. The FTC is investigating Mylan's efforts to stave off generic versions of its blockbuster device.
Two months after U.S. lawmakers called for an investigation into the insulin market, Novo Nordisk faces a potential class-action lawsuit for its role in alleged “collusive price fixing.”
Months into a bruising EpiPen pricing scandal, congressional scrutiny on Mylan continues to heat up. Top members of the Senate Judiciary Committee have called on the Federal Trade Commission to examine whether the company--already under several investigations--used anticompetitive practices to pad its revenues for its important epinephrine injector.
Pharma deals are already coming under the antitrust lens more often than tie-ups in other industries. And as long as drug prices keep rising, that’s not going to change.
Pharma needs to set its guidelines for native advertising now, experts advise, after a new study called out marketers for breaking FTC rules on labeling paid content.